The global preventive vaccines market is projected to be worth USD 94 billion, by 2030
Key Market Insights
- More than 200 preventive vaccines, developed by both industry and non-industry players, are being evaluated in clinical stages of development
- A variety of vaccine APIs, designed for administration via multiple routes of delivery, are presently being investigated; most such candidates are in the early stages of development
- In order to achieve a competitive edge, vaccine developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent
- Foreseeing a lucrative future in this domain, several private and public investors have invested close to USD 10 billion in vaccine development initiatives, across 170 instances, in the time period between 2015 and 2020
- Over the last few years, 1,400+ clinical trials evaluating various types of preventive vaccines have been registered, indicating the rapid pace of development in this field
- Case-in-Point: Around 70 companies, situated in different regions across the globe, claim to provide contract development, fill / finish and regulatory support, in addition to manufacturing services
- The market is anticipated to grow at a CAGR of 10.7%, till 2030, and the projected opportunity is likely to be distributed across various routes of administration, vaccine types and key geographical regions
-
Table of Contents
-
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION3.1. Chapter Overview
3.2. Preventive Vaccines
3.2.1. Classification of Vaccines
3.2.1.1. Live, Attenuated Vaccines
3.2.1.2. Inactivated Vaccines
3.2.1.3. Subunit Vaccines
3.2.1.4. Toxoid Vaccines
3.2.1.5. DNA Vaccines
3.2.2. Key Components of a Vaccine Formulation
3.2.3. Production of Vaccines using Different Expression Systems
3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.2.3.2. Mammalian Expression Systems
3.2.3.3. Avian Expression Systems
3.2.3.4. Plant Expression Systems
3.2.3.5. Bacterial Expression Systems
3.2.3.6. Yeast Expression Systems
3.2.3.7. Insect Expression System
3.2.4. Routes of Vaccine Administration
3.2.4.1. Intramuscular Route
3.2.4.2. Subcutaneous Route
3.2.4.3. Oral Route
3.2.4.4. Intranasal Route
3.2.4.5. Intradermal Route
3.2.4.6. Inhalation
3.2.5. Clinical Development and Approval of Vaccines
3.2.6. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Preventive Vaccines: Overall Market Landscape
4.2.1. Marketed Vaccines Landscape
4.2.2. Clinical-Stage Vaccines Landscape
4.2.2.1. Analysis by Type of Developer
4.2.2.2. Analysis by Phase of Development
4.2.2.3. Analysis by Route of Administration
4.2.2.4. Analysis by Type of Vaccine API
4.2.2.5. Analysis by Dosage Form
4.2.2.6. Analysis by Dosage
4.2.2.7. Analysis by Target Disease Indication
4.2.2.8. Analysis by Target Patient Population
4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Preventive Vaccine Developers
5.4.1. Preventive Vaccine Developers based in North America
5.4.2. Preventive Vaccine Developers based in Europe
5.4.3. Preventive Vaccine Developers based in Asia Pacific
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Bio Farma
6.2.1. Company Overview
6.2.2. Preventive Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Emergent BioSolutions
6.3.1. Company Overview
6.3.2. Preventive Vaccines Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. GC Pharma
6.4.1. Company Overview
6.4.2. Preventive Vaccines Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. GlaxoSmithKline
6.5.1. Company Overview
6.5.2. Preventive Vaccines Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Janssen
6.6.1. Company Overview
6.6.2. Preventive Vaccines Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Merck
6.7.1. Company Overview
6.7.2. Preventive Vaccines Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Novavax
6.8.1. Company Overview
6.8.2. Preventive Vaccines Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Pfizer
6.9.1. Company Overview
6.9.2. Preventive Vaccines Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Sanofi Pasteur
6.10.1. Company Overview
6.10.2. Preventive Vaccines Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. Valneva
6.11.1. Company Overview
6.11.2. Preventive Vaccines Portfolio
6.11.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Preventive Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Study Design
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen)
7.3.8. Analysis by Target Disease Indication
7.3.9. Analysis by Type of Sponsor / Collaborator
Molded Fiber Plates Market Size, Industry Development and Top Key Players Analysis 2019-2026
- Global Molded Fiber Plates Market Report 2019 to 2026
Maritime Rescue Service said. The spokesman told The Associated Press that rescuers were looking for more survivors in the ocean.
- Maritime Rescue Service said. The spokesman told The Associated Press that rescuers were looking for more survivors in the ocean.
Salesforce PDI Exam Dumps & Platform Developer I PDF Dumps Certification
- PDI exam | PDI exam dumps | Salesforce PDI exam | PDI practice exam | PDI actual exam | PDI braindumps | PDI questions & answers | PDI pdf dumps
Easy Way to Clear 220-1002 Exam ~ Get 220-1002 Dumps PDF
- Get latest and updated exam material from mockdumps with passing guarantee in first try. We provide 24/7 customer support to our honorable students